---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019030"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:21:43.363495+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech Q3 net revenue $34.8M (up 100% QoQ); net loss narrows to $7.1M

## Summary
- Total consolidated net revenue $34.8M, including $19M upfront payment from Journey Medical's Maruho license.
- Net loss attributable to common stockholders $7.1M ($0.94/share) vs $24.5M ($4.11) in Q3 2022.
- Cash, equivalents and restricted cash $74.7M at Sept 30; subsequent public offering raised $10M in Nov 2023.
- NDA for DFD-29 (rosacea) expected around year-end 2023; cosibelimab PDUFA date Jan 3, 2024.
- Effected 1-for-15 reverse stock split in Oct 2023 to meet Nasdaq minimum bid price requirement.

## SEC filing metadata
- accession: 0001558370-23-019030
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837023019030/0001558370-23-019030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837023019030/fbio-20231114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019030
- JSON: https://secwatch.observer/filing/0001558370-23-019030.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019030.txt

## Key facts
- Earnings Releases
  Fortress Biotech, Inc. reported third quarter ended September 30, 2023 results: revenue $34.8 million.
  - Period: third quarter ended September 30, 2023
  - Revenue: $34.8 million
  - Result: reported results
  source text: in such filing. ​ --- EX-99.1 (EX-99.1) --- Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights ​ Total consolidated net revenue was $34.8 million in the third quarter of 2023, a 100% increase from total consolidated net revenue of $17.4 million in the second quarter of 2023 ​ Fortress is advancing several late-stage
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000155837023019030/0001558370-23-019030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.